RG
TVRD

Rathbones Group’s Tvardi Therapeutics TVRD Stock Holding History

Rathbones Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,721
Closed -$7.16K – 640
2024
Q4 		$7.16K Buy
6,721
+6,161
+1,100% +$67.1K ﹤0.01% 605
2024
Q3 		$6.21K Hold
560
– – ﹤0.01% 602
2024
Q2 		$5.2K Hold
560
– – ﹤0.01% 614
2024
Q1 		$18.3K Hold
560
– – ﹤0.01% 607
2023
Q4 		$15K Hold
560
– – ﹤0.01% 607
2023
Q3 		$33.9K Buy
560
+4
+0.7% +$375 ﹤0.01% 603
2023
Q2 		$56.6K Hold
556
– – ﹤0.01% 400
2023
Q1 		$98.2K Hold
556
– – ﹤0.01% 392
2022
Q4 		$215K Hold
556
– – ﹤0.01% 369
2022
Q3 		$187K Hold
556
– – ﹤0.01% 376
2022
Q2 		$183K Hold
556
– – ﹤0.01% 392
2022
Q1 		$243K Hold
556
– – ﹤0.01% 377
2021
Q4 		$244K Hold
556
– – ﹤0.01% 382
2021
Q3 		$309K Buy
556
+167
+43% +$83.8K ﹤0.01% 350
2021
Q2 		$200K Sell
389
-139
-26% -$88.1K ﹤0.01% 401
2021
Q1 		$412K Hold
528
– – 0.01% 309
2020
Q4 		$287K Hold
528
– – ﹤0.01% 335
2020
Q3 		$242K Hold
528
– – ﹤0.01% 330
2020
Q2 		$325K Hold
528
– – 0.01% 281
2020
Q1 		$251K Hold
528
– – 0.01% 265
2019
Q4 		$306K Hold
528
– – 0.01% 271
2019
Q3 		$347K Buy
528
+56
+12% +$46.6K 0.01% 266
2019
Q2 		$366K Hold
472
– – 0.01% 250
2019
Q1 		$334K Buy
472
+28
+6% +$16.8K 0.01% 255
2018
Q4 		$208K Buy
444
+180
+68% +$116K 0.01% 287
2018
Q3 		$228K Buy
+264
New +$191K 0.01% 272
2017
Q3 		– Sell
-333
Closed -$185K – 326
2017
Q2 		$185K Buy
+333
New +$211K 0.01% 288

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rathbones Group's TVRD Position: Q1 2025 in Review

Rathbones Group sold out of Tvardi Therapeutics (TVRD) in Q1 2025, closing a stake of 6,721 shares — an estimated $7.16K sold.

Rathbones Group first reported a position in TVRD in Q2 2017 and held it in 27 quarters. The position peaked at $412K in Q1 2021. 33 funds tracked by Wall St. Rank hold TVRD as of Q1 2025.

  • Rathbones Group reported no remaining Tvardi Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Rathbones Group sold 6,721 Tvardi Therapeutics shares in Q1 2025, an estimated $7.16K.
  • Rathbones Group first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 27 quarters.
  • Rathbones Group's Tvardi Therapeutics position peaked at $412K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2025.

Based on Rathbones Group's 13F filing for Q1 2025, filed 13 May 2025.